ASTRAZENECA PRICES A $6 BILLION BOND ISSUE

AstraZeneca PLC announces that yesterday it conducted a global bond market
transaction by issuing a total of $6bn of notes. The proceeds of the issue will
be used to fund the previously announced acquisition of ZS Pharma, Inc., to
repay certain outstanding commercial paper obligations, and for general
corporate purposes. The transaction, which is a global offering registered with
the US Securities and Exchange Commission (SEC), consists of five tranches:

·     $0.4bn of 3-year floating rate notes;

·     $1.0bn of 3-year fixed rate notes with a coupon of 1.750%;

·     $1.6bn of 5-year fixed rate notes with a coupon of 2.375%;

·     $2.0bn of 10-year fixed rate notes with a coupon of 3.375%; and

·     $1.0bn of 30-year fixed rate notes with a coupon of 4.375%.

The notes will be issued under AstraZeneca's existing automatic shelf
registration statement on Form F-3, which AstraZeneca filed with the SEC on 26
November 2013. Such registration statement provides for the offer and sale from
time to time of an indeterminate amount of AstraZeneca's debt securities and
includes a prospectus that investors should read to obtain more complete
information. The offering was made solely by means of a written prospectus
forming part of the effective registration statement.

A copy of the prospectus supplement and accompanying prospectus relating to the
offering can be obtained by contacting Barclays Capital Inc. at +1 888 603 5847,
HSBC Securities (USA) Inc at +1 866 811 8049, Merrill Lynch, Pierce, Fenner &
Smith Incorporated at +1 800 294 1322 or Morgan Stanley & Co. LLC at +1 866 718
1649. You may also get these documents for free by visiting EDGAR on the SEC
website at www.sec.gov.

This announcement shall not constitute an offer to sell or the solicitation of
an offer to buy, nor shall there be any sale of these securities in any
jurisdiction in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any such
jurisdiction.

The bond issuance does not have any material impact to the Company's financial
guidance for 2015.

11 November 2015

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that
focuses on the discovery, development and commercialisation of prescription
medicines, primarily for the treatment of cardiovascular, metabolic,
respiratory, inflammation, autoimmune, oncology, infection and neuroscience
diseases. AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide. For more information about
AstraZeneca please visit: www.astrazeneca.com.

CONTACTS

Media Enquiries
Esra Erkal-Paler                          UK/Global         +44 20 7604 8030
Vanessa Rhodes                            UK/Global         +44 20 7604 8037
Ayesha Bharmal                            UK/Global         +44 20 7604 8034
Karen Birmingham                          UK/Global         +44 20 7604 8120
Jacob Lund                                Sweden            +46 8 553 260 20
Michele Meixell                           US                +1 302 885 2677
Investor Enquiries
UK
Thomas Kudsk Larsen  Oncology             +44 20 7604 8199  +44 7818 524185
Eugenia Litz         RIA                  +44 20 7604 8233  +44 7884 735627
Nick Stone           CVMD                 +44 1763 263 994  +44 7717 618834
Craig Marks          Finance              +44 20 7604 8591  +44 7881 615764
Christer Gruvris     Consensus Forecasts  +44 20 7604 8126  +44 7827 836825
US
Lindsey Trickett     Oncology, ING        +1 301 398 5118   +1 240 543 7970
Mitch Chan           Oncology             +1 301 398 1849   +1 240 477 3771
Dial / Toll-Free                          +1 301 398 3251   +1 866 381 7277

Key: RIA - Respiratory, Inflammation and Autoimmunity, CVMD - Cardiovascular and
Metabolic Disease,

ING - Infection, Neuroscience and Gastrointestinal